Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (original) (raw)
- Article
- Published: 22 November 2009
- David W. White1,
- Stefan Gross1,
- Bryson D. Bennett2,
- Mark A. Bittinger1,
- Edward M. Driggers1,
- Valeria R. Fantin1,
- Hyun Gyung Jang1,
- Shengfang Jin1,
- Marie C. Keenan1,
- Kevin M. Marks1,
- Robert M. Prins3,
- Patrick S. Ward4,
- Katharine E. Yen1,
- Linda M. Liau3,
- Joshua D. Rabinowitz2,
- Lewis C. Cantley5,
- Craig B. Thompson4,
- Matthew G. Vander Heiden1 nAff6 &
- …
- Shinsan M. Su1
Nature volume 462, pages 739–744 (2009)Cite this article
- 42k Accesses
- 2825 Citations
- 91 Altmetric
- Metrics details
An Addendum to this article was published on 17 June 2010
Abstract
Mutations in the enzyme cytosolic isocitrate dehydrogenase 1 (IDH1) are a common feature of a major subset of primary human brain cancers. These mutations occur at a single amino acid residue of the IDH1 active site, resulting in loss of the enzyme’s ability to catalyse conversion of isocitrate to α-ketoglutarate. However, only a single copy of the gene is mutated in tumours, raising the possibility that the mutations do not result in a simple loss of function. Here we show that cancer-associated IDH1 mutations result in a new ability of the enzyme to catalyse the NADPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG). Structural studies demonstrate that when arginine 132 is mutated to histidine, residues in the active site are shifted to produce structural changes consistent with reduced oxidative decarboxylation of isocitrate and acquisition of the ability to convert α-ketoglutarate to 2HG. Excess accumulation of 2HG has been shown to lead to an elevated risk of malignant brain tumours in patients with inborn errors of 2HG metabolism. Similarly, in human malignant gliomas harbouring IDH1 mutations, we find markedly elevated levels of 2HG. These data demonstrate that the IDH1 mutations result in production of the onco-metabolite 2HG, and indicate that the excess 2HG which accumulates in vivo contributes to the formation and malignant progression of gliomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
Accession codes
Primary accessions
Protein Data Bank
Data deposits
R132H mutant IDH1 structure files are deposited in the Protein Data Bank under accession code 3INM.
References
- Balss, J. et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116, 597–602 (2008)
Article CAS Google Scholar - Watanabe, T., Nobusawa, S., Kleihues, P. & Ohgaki, H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 174, 1149–1153 (2009)
Article CAS Google Scholar - Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009)
Article CAS Google Scholar - Hartmann, C. et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 118, 469–474 (2009)
Article Google Scholar - Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807–1812 (2008)
Article ADS CAS Google Scholar - Bleeker, F. E. et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum. Mutat. 30, 7–11 (2009)
Article CAS Google Scholar - Zhao, S. et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324, 261–265 (2009)
Article ADS CAS Google Scholar - Lu, W., Kimball, E. & Rabinowitz, J. D. A high-performance liquid chromatography-tandem mass spectrometry method for quantitation of nitrogen-containing intracellular metabolites. J. Am. Soc. Mass Spectrom. 17, 37–50 (2006)
Article CAS Google Scholar - Struys, E. A., Jansen, E. E., Verhoeven, N. M. & Jakobs, C. Measurement of urinary d- and l-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography-tandem mass spectrometry after derivatization with diacetyl-l-tartaric anhydride. Clin. Chem. 50, 1391–1395 (2004)
Article CAS Google Scholar - Xu, X. et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J. Biol. Chem. 279, 33946–33957 (2004)
Article CAS Google Scholar - Aktas, D. F. & Cook, P. F. A lysine-tyrosine pair carries out acid-base chemistry in the metal ion-dependent pyridine dinucleotide-linked β-hydroxyacid oxidative decarboxylases. Biochemistry 48, 3565–3577 (2009)
Article CAS Google Scholar - Struys, E. A. et al. Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. Am. J. Hum. Genet. 76, 358–360 (2005)
Article CAS Google Scholar - Kölker, S., Mayatepek, E. & Hoffmann, G. F. White matter disease in cerebral organic acid disorders: clinical implications and suggested pathomechanisms. Neuropediatrics 33, 225–231 (2002)
Article Google Scholar - Wajner, M., Latini, A., Wyse, A. T. & Dutra-Filho, C. S. The role of oxidative damage in the neuropathology of organic acidurias: insights from animal studies. J. Inherit. Metab. Dis. 27, 427–448 (2004)
Article CAS Google Scholar - Aghili, M., Zahedi, F. & Rafiee, E. Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J. Neurooncol. 91, 233–236 (2009)
Article Google Scholar - Kolker, S. et al. NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d-2-hydroxyglutaric aciduria. Eur. J. Neurosci. 16, 21–28 (2002)
Article Google Scholar - Latini, A. et al. d-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats. Eur. J. Neurosci. 17, 2017–2022 (2003)
Article Google Scholar - Tsacopoulos, M. Metabolic signaling between neurons and glial cells: a short review. J. Physiol. (Paris) 96, 283–288 (2002)
Article CAS Google Scholar - Mardis, E. R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058–1066 (2009)
Article CAS Google Scholar - Luo, B., Groenke, K., Takors, R., Wandrey, C. & Oldiges, M. Simultaneous determination of multiple intracellular metabolites in glycolysis, pentose phosphate pathway and tricarboxylic acid cycle by liquid chromatography-mass spectrometry. J. Chromatogr. A 1147, 153–164 (2007)
Article CAS Google Scholar - Munger, J. et al. Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nature Biotechnol. 26, 1179–1186 (2008)
Article CAS Google Scholar - Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode (HKL2000). Methods Enzymol. 276, 307–326 (1997)
Article CAS Google Scholar - McCoy, A. J. et al. Phaser Crystallographic Software. J. Appl. Cryst. 40, 658–674 (2007)
Article CAS Google Scholar - Emsley, P. & Cowtan, K. COOT: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126–2132 (2004)
Article Google Scholar - Collaborative Computational Project, Number 4. The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr. D 50, 760–763 (1994)
- DeLano, W. L. The PyMOL Molecular Graphics System (DeLano Scientific, 2002)
Google Scholar
Acknowledgements
We thank R. K. Suto, R. S. Brown and E. Fontano at Xtal BioStructures for performing crystallographic studies, and S. Wang at ChemPartner for assistance with biochemical experiments. We thank G. Petsko for his review of the structure data. We also thank T. Mak, N. Wu, L. Tartaglia, J. Saunders, F. Salituro and D. Schenkein for discussions and/or comments on the manuscript. Asterand, PLC provided some of the glioma specimens and SeqWright Inc. assisted with genomic DNA SNP analysis. J.D.R. is supported by NIH R21 CA128620.
Author Contributions L.D., D.W.W., S.G., B.D.B., M.A.B., E.M.D., V.R.F., H.G.J., S.J., M.C.K., K.M.M., R.M.P., P.S.W., K.E.Y., J.D.R., L.M.L. and S.M.S. contributed extensively to the work presented in this paper. L.C.C., C.B.T., M.G.V.H. and S.M.S. provided support and conceptual advice. L.D., M.G.V.H. and S.M.S. wrote the manuscript.
Author information
Author notes
- Matthew G. Vander Heiden
Present address: Present address: Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.,
Authors and Affiliations
- Agios Pharmaceuticals, Cambridge, Massachusetts 02139, USA ,
Lenny Dang, David W. White, Stefan Gross, Mark A. Bittinger, Edward M. Driggers, Valeria R. Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C. Keenan, Kevin M. Marks, Katharine E. Yen, Matthew G. Vander Heiden & Shinsan M. Su - Department of Chemistry and Integrative Genomics, Princeton University, Princeton, New Jersey 08544, USA,
Bryson D. Bennett & Joshua D. Rabinowitz - Department of Neurosurgery, UCLA Medical School, Los Angeles, California 90095, USA,
Robert M. Prins & Linda M. Liau - Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA ,
Patrick S. Ward & Craig B. Thompson - Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA ,
Lewis C. Cantley
Authors
- Lenny Dang
You can also search for this author inPubMed Google Scholar - David W. White
You can also search for this author inPubMed Google Scholar - Stefan Gross
You can also search for this author inPubMed Google Scholar - Bryson D. Bennett
You can also search for this author inPubMed Google Scholar - Mark A. Bittinger
You can also search for this author inPubMed Google Scholar - Edward M. Driggers
You can also search for this author inPubMed Google Scholar - Valeria R. Fantin
You can also search for this author inPubMed Google Scholar - Hyun Gyung Jang
You can also search for this author inPubMed Google Scholar - Shengfang Jin
You can also search for this author inPubMed Google Scholar - Marie C. Keenan
You can also search for this author inPubMed Google Scholar - Kevin M. Marks
You can also search for this author inPubMed Google Scholar - Robert M. Prins
You can also search for this author inPubMed Google Scholar - Patrick S. Ward
You can also search for this author inPubMed Google Scholar - Katharine E. Yen
You can also search for this author inPubMed Google Scholar - Linda M. Liau
You can also search for this author inPubMed Google Scholar - Joshua D. Rabinowitz
You can also search for this author inPubMed Google Scholar - Lewis C. Cantley
You can also search for this author inPubMed Google Scholar - Craig B. Thompson
You can also search for this author inPubMed Google Scholar - Matthew G. Vander Heiden
You can also search for this author inPubMed Google Scholar - Shinsan M. Su
You can also search for this author inPubMed Google Scholar
Corresponding author
Correspondence toShinsan M. Su.
Ethics declarations
Competing interests
L.D., D.W.W., S.G., M.A.B., E.M.D., V.R.F., H.G.J., S.J., M.C.K., K.M.M., K.E.Y., J.D.R., L.C.C, C.B.T., M.G.V.H. and S.M.S. are employees or consultants of Agios Pharmaceuticals and have financial interest in Agios.
Supplementary information
Supplementary Information
This file contains Supplementary Figures 1-5 with Legends and Supplementary Tables 1-2. (PDF 663 kb)
PowerPoint slides
Rights and permissions
About this article
Cite this article
Dang, L., White, D., Gross, S. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.Nature 462, 739–744 (2009). https://doi.org/10.1038/nature08617
- Received: 15 July 2009
- Accepted: 29 October 2009
- Published: 22 November 2009
- Issue Date: 10 December 2009
- DOI: https://doi.org/10.1038/nature08617
This article is cited by
Editorial Summary
Role of 2-hydroxyglutarate in cancer
A high percentage of human glioblastomas has been found to harbour mutations in the metabolic enzyme cytosolic isocitrate dehydrogenase 1 (IDH1). The predominant R132H mutation is now shown to act as a gain-of-function mutation, enabling IDH1 to convert α-ketoglutarate to 2-hydroxyglutarate (2-HG). Human glioblastoma samples with IDH1 mutations indeed contain elevated levels of 2-HG. Future work will be directed at understanding the mechanisms by which 2-HG can contribute to tumorigenesis.